ANVS icon

Annovis Bio

3.08 USD
-0.06
1.91%
At close Feb 6, 4:00 PM EST
After hours
3.07
-0.01
0.32%
1 day
-1.91%
5 days
-36.23%
1 month
-42.43%
3 months
-64.10%
6 months
-63.11%
Year to date
-39.73%
1 year
-69.98%
5 years
-50.00%
10 years
-67.88%
 

About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Employees: 6

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

67% more capital invested

Capital invested by funds: $5.7M [Q2] → $9.53M (+$3.83M) [Q3]

13% more funds holding

Funds holding: 31 [Q2] → 35 (+4) [Q3]

0.2% more ownership

Funds ownership: 8.86% [Q2] → 9.06% (+0.2%) [Q3]

72% less call options, than puts

Call options by funds: $3.33M | Put options by funds: $12M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$21
582%
upside
Avg. target
$26
728%
upside
High target
$30
874%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
D. Boral Capital
Jason Kolbert
31% 1-year accuracy
67 / 214 met price target
582%upside
$21
Buy
Maintained
11 Nov 2024
HC Wainwright & Co.
Raghuram Selvaraju
40% 1-year accuracy
130 / 329 met price target
874%upside
$30
Buy
Reiterated
11 Nov 2024

Financial journalist opinion

Based on 5 articles about ANVS published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD.
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease
Neutral
GlobeNewsWire
2 days ago
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share and associated warrant. The warrants have an exercise price of $5.00 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance. Total gross proceeds from the offering, before deducting the underwriter's discounts and other offering expenses, were $21 million.
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
Neutral
GlobeNewsWire
3 days ago
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share. The warrants will have an exercise price of $5.00 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts and other offering expenses, are expected to be $21 million. The offering is expected to close on February 4, 2025, subject to satisfaction of customary closing conditions
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
Neutral
GlobeNewsWire
5 days ago
Annovis Bio, Inc. Announces Proposed Public Offering
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company.
Annovis Bio, Inc. Announces Proposed Public Offering
Neutral
GlobeNewsWire
3 weeks ago
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap.
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
Neutral
GlobeNewsWire
2 months ago
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio's (NYSE: ANVS) recent feature on Today's Marketplace (TMP) as part of its commitment to amplifying industry leaders' voices through targeted distribution channels.
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
Neutral
PRNewsWire
2 months ago
/C O R R E C T I O N -- Today's Marketplace/
In the news release, Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace, issued 04-Dec-2024 by Today's Marketplace over PR Newswire, we are advised by the company that in the Annovis boilerplate, the first sentence should include the stock ticker (NYSE: ANVS) as originally issued inadvertently. The complete, corrected release follows: Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace NEW YORK , Dec. 4, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Annovis' Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University's Institute for Population Health.
/C O R R E C T I O N -- Today's Marketplace/
Neutral
GlobeNewsWire
2 months ago
Annovis to Host Year-End Investor Webcast on December 11, 2024
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased to announce a live investor webcast scheduled for December 11, 2024, at 4:30 PM EST.
Annovis to Host Year-End Investor Webcast on December 11, 2024
Neutral
GlobeNewsWire
3 months ago
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
Neutral
GlobeNewsWire
3 months ago
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs
MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy.
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs
Charts implemented using Lightweight Charts™